Skip to main content
NCBI home page
BMC Pulmonary Medicine logoLink to BMC Pulmonary Medicine
. 2020 May 7;20:131. doi: 10.1186/s12890-020-1118-x

Correction to: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis

Takumi Yoshikawa 1,#, Mitsuo Otsuka 1,✉, Hirofumi Chiba 1,#, Kimiyuki Ikeda 1, Yuki Mori 1, Yasuaki Umeda 1, Hirotaka Nishikiori 1, Koji Kuronuma 1, Hiroki Takahashi 1
PMCID: PMC7206697  PMID: 32380992

Correction to: BMC Pulm Med (2020) 20:27

https://doi.org/10.1186/s12890-020-1060-y

Following publication of the original article [1], the authors have flagged that there is an error in Fig. 3.

Fig. 3.

Fig. 3

Open in a new tab

Relative change in SP-A, SP-D, and KL-6 levels in the initial 3 and 6 months in the stable and progression groups. Changes in SP-A at 3 and 6 months, SP-D at 6 months, and KL-6 at 3 and 6 months were significantly smaller in the stable group than the progression group (*p < 0.05). Data were analyzed by Mann-Whitney U test. Horizontal line indicates median concentration. The upper and lower limits of the box indicate the inter-quartile range

Namely, asterisks indicating significant difference are missing in the figure.

Please see the correct version of Fig. 3 in this correction article.

The authors apologize for any inconvenience caused.

Footnotes

Takumi Yoshikawa and Hirofumi Chiba contributed equally to this work.

Reference

  • 1.Yoshikawa T, et al. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis. BMC Pulm Med. 2020;20:27. doi: 10.1186/s12890-020-1060-y. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMC Pulmonary Medicine are provided here courtesy of BMC

RESOURCES